Terms: = Breast cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Treatment
676 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
3. Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
4. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract] [Full Text] [Related]
5. Uncovering the effect and mechanism of Jiawei Xiaoyao Wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis.
Bai Y; Niu L; Song L; Dai G; Zhang W; He B; San W; Li S
Phytomedicine; 2024 Jun; 128():155427. PubMed ID: 38513380
[TBL] [Abstract] [Full Text] [Related]
6. Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/JAK2/stat3 signal pathway.
Shi X; Lai Y; Liu W; Zhang X; Cang Y
Biochem Biophys Res Commun; 2024 Apr; 706():149758. PubMed ID: 38484571
[TBL] [Abstract] [Full Text] [Related]
7. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
8. Combination of stat3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
9. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
10. Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches.
Gu M; Liu Y; Xin P; Guo W; Zhao Z; Yang X; Ma R; Jiao T; Zheng W
Cancer Lett; 2024 Apr; 588():216738. PubMed ID: 38401887
[TBL] [Abstract] [Full Text] [Related]
11. The IL6/JAK/stat3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Amara CS; Kami Reddy KR; Yuntao Y; Chan YS; Piyarathna DWB; Dobrolecki LE; Shih DJH; Shi Z; Xu J; Huang S; Ellis MJ; Apolo AB; Ballester LY; Gao J; Hansel DE; Lotan Y; Hodges HC; Lerner SP; Creighton CJ; Sreekumar A; Zheng WJ; Msaouel P; Kavuri SM; Putluri N
Nat Commun; 2024 Feb; 15(1):1373. PubMed ID: 38355560
[TBL] [Abstract] [Full Text] [Related]
12. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative breast cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/stat3 Signaling.
Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD
Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147
[TBL] [Abstract] [Full Text] [Related]
13. The obeticholic acid can positively regulate the cancerous behavior of MCF7 breast cancer cell line.
Rahmani R; Eivazi N; Emamgholipour S; Aminian M; Jalilian A; Paknejad M
Mol Biol Rep; 2024 Feb; 51(1):250. PubMed ID: 38302816
[TBL] [Abstract] [Full Text] [Related]
14. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract] [Full Text] [Related]
15. Gaillardin inhibits autophagy and induces apoptosis in MCF-7 breast cancer cells by regulating JAK/STAT pathway.
Rajabi S; Tahmasvand Z; Maresca M; Hamzeloo-Moghadam M
Mol Biol Rep; 2024 Jan; 51(1):158. PubMed ID: 38252203
[TBL] [Abstract] [Full Text] [Related]
16. Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21.
Sui Y; Liu Q; Xu C; Ganesan K; Ye Z; Li Y; Wu J; Du B; Gao F; Song C; Chen J
Cell Death Dis; 2024 Jan; 15(1):67. PubMed ID: 38238320
[TBL] [Abstract] [Full Text] [Related]
17. Development of new thieno[2,3-d]pyrimidines as dual EGFR and stat3 inhibitors endowed with anticancer and pro-apoptotic activities.
Elsebaie HA; El-Moselhy TF; El-Bastawissy EA; Elberembally KM; Badi RM; Elkaeed EB; Shaldam MA; Eldehna WM; Tawfik HO
Bioorg Chem; 2024 Feb; 143():107101. PubMed ID: 38183682
[TBL] [Abstract] [Full Text] [Related]
18. A bibliometric and visual analysis of cancer-associated fibroblasts.
Yuan WC; Zhang JX; Chen HB; Yuan Y; Zhuang YP; Zhou HL; Li MH; Qiu WL; Zhou HG
Front Immunol; 2023; 14():1323115. PubMed ID: 38173726
[TBL] [Abstract] [Full Text] [Related]
19. Brain Metastases Are Regulated by Immuno-inflammatory Signaling Pathways Governed by stat3, MAPK and Tumor Suppressor p53 Status: Possible Therapeutic Targets.
Zeller SL; Spirollari E; Dicpinigaitis AJ; Wainwright JV; Hanft SJ; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2024 Jan; 44(1):13-22. PubMed ID: 38160007
[TBL] [Abstract] [Full Text] [Related]
20. In Vitro and In Vivo Anti-cancer Activity of Lasiokaurin in a Triple-Negative breast cancer Model.
Lin J; Qu Z; Pu H; Shen LS; Yi X; Lin YS; Gong RH; Chen GQ; Chen S
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067432
[TBL] [Abstract] [Full Text] [Related]
[Next]
